Yes, rapamycin alleviates intrahepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). According to the study, rapamycin's therapeutic effects are primarily mediated through its action on bone marrow-derived macrophages, which are key immune cells involved in liver inflammation.
Yes, rapamycin alleviates intrahepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). According to the study, rapamycin's therapeutic effects are primarily mediated through its action on bone marrow-derived macrophages, which are key immune cells involved in liver inflammation.
Rapamycin suppresses the proinflammatory activation of hepatic macrophages and enhances pathways related to fatty acid oxidation within these cells. By promoting fatty acid oxidation in macrophages, rapamycin reduces their inflammatory capacity, thereby creating a less inflammatory hepatic microenvironment. This reprogramming of macrophage metabolism toward an anti-inflammatory state is a key mechanism by which rapamycin mitigates intrahepatic inflammation in MASLD.
Thus, rapamycin offers a promising approach to targeting inflammation in MASLD and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH). However, it is important to note that while rapamycin improves hepatic inflammation, steatosis, and steatohepatitis, it does not have a significant impact on established liver fibrosis.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.